Vimal Mehta

This profile gathers the share dealings of Vimal Mehta in BioXcel Therapeutics, Inc., where the filings describe the role as chief executive. Over a trading history stretching from 25 June 2021 to 15 June 2026, the count stands at 24 filings.

The open-market record consists of 4 sales worth €12.4M, with no purchase. The totals exclude 1 filing filed without an amount. Outside the open market, there are 1 share grant and 19 option exercises. In 2026 alone, the filings show no purchases and 1 sale.

The record was last updated on 17 June 2026 with an option exercise in BioXcel Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.